Navigation Links
World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients

ZURICH, July 19, 2010 /PRNewswire/ -- Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.[1]

Spanning 28 countries across 4 continents and involving more than 3300 physicians, A1chieve(R) is set to be the world's largest observational study in insulin therapy.

Approximately 70 percent of the world's 285 million people with diabetes are living in these 28 emerging countries where there is a rising need and interest to look at differences in physician decisions in the management of diabetes.[2]

"Multinational observational studies like A1chieve(R) provide valuable insights in the way current therapies are applied when it comes to varying cultural, economic and epidemiological circumstances," said Philip Home, Professor of Diabetes Medicine at Newcastle University England and Chair of the A1chieve(R) Global Advisory Board.

In order to mimic the natural secretion of insulin in the body, commercially available insulin preparations are used in different ways (regimens) based on an individual's need and prevailing local practices. However it is important to evaluate these different regimens in a real life setting.

"Once completed A1chieve(R) will provide locally relevant information on the effective use of modern insulins across different regimens. This information could be further useful to inform and improve the local guidelines on the management of type 2 diabetes" added Professor Home.

Jesper H0iland, Senior Vice President, Novo Nordisk Region International Operations A/S said "The A1chieve(R) study is another major initiative demonstrating our commitment as leaders in the field of diabetes care. Our vast experience and unmatched presence in the emerging countries has enabled us to carry out such a unique and large scale research activity of clinical importance."

The results of this multinational study will be available in 2011.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 28,500 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit

    Further information:


    1. Siddharth N. Shah, Leon Litwak, Jihad Haddad, Praful N. Chakkarwar and
    Issam Hajjaji. The A1chieve(R) study: a 60,000-person, global,
    prospective, observational study of basal, meal, and biphasic insulin
    analogs in daily clinical practice. Diabetes Research and Clinical
    Practice 88S (2010).

    2. IDF Diabetes Atlas 4th Edition, International Diabetes Federation,

SOURCE Novo Nordisk
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
2. Frankfurt To Host Worlds Largest Pharmaceutical Services Events In 2011
3. Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Largest Civil Settlement in Pharmaceutical Case Announced by U.S. Department of Justice
5. CyberKnife Radiosurgery Now Reimbursed Throughout France and Largest Italian Region
6. First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity
7. New York States Largest Integrated Health System Chooses Craneware Revenue Integrity Solutions
8. Russias Largest Breast Cancer Oncology Center Uses New CAD Software for Advanced Breast Cancer Detection
9. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
10. U.S. Files Suit Against Johnson & Johnson For Paying Kickbacks to Nations Largest Nursing Home Pharmacy
11. At Nearly $120 Million, The Hepatitis C Drug Market in Brazil is Among the Largest Emerging Pharmaceutical Markets for the Disease
Post Your Comments:
(Date:12/1/2015)... , December 1, 2015 ... Contraceptive Injectables, Topical Contraceptives, Male Condoms, Female ... Vaginal Rings, Contraceptive Diaphragms, Contraceptive Sponges, Non-Surgical ... Size, Share, Growth, Trends and Forecast 2014 ... Transparency Market Research (TMR).The report states that ...
(Date:12/1/2015)... 1, 2015  InCarda Therapeutics, Inc. (InCarda), a privately-held ... therapies for cardiovascular conditions via the inhalation route, today ... Australia . InCarda is planning to ... Australia in the first half of 2016. ... centers in Adelaide and Melbourne.  ...
(Date:12/1/2015)... 2015 ) ... Alert Systems/Personal Emergency Response System (PERS) Market by ... Forecas" report to their offering. --> ... the "Medical Alert Systems/Personal Emergency Response System ... Geography - Global Forecas" report to their ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center Jacksonville has ... the only hospital in the region providing what is known as the world’s ... patients were revealed recently at a medical conference and published in The New ...
(Date:12/1/2015)... TX (PRWEB) , ... December 01, 2015 , ... Dr. ... of Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best Single ... of the best among the many elite aesthetic physicians honored by the industry publication. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments ... to decreases in utilization of hospital and nonhospital care, according to a recent study ... Benchmarks for Louisiana, 16th Edition , found medical payments per claim with more than ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... the 1980s we have seen vast improvements in scientific research and discoveries, leading ... strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform ...
(Date:12/1/2015)... ... , ... It’s official: Tattoo taboo is a thing of the past. One ... (a whopping one in three aged 18 to 25 is inked). As tattoos transition ... ink. In fact, RealSelf , the world’s largest community for learning and sharing ...
Breaking Medicine News(10 mins):